Guardant Health, Inc. (GH)
Sector: Healthcare
Industry: Services-Medical Laboratories
Country: United States
Exchange: NASDAQ
Market cap: $24.07B
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Latest financial period: June 30, 2026
Filed with the SEC: July 30, 2026
Estimated earnings date: November 4, 2026
Profit #1482 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROIC | -182.3% | -141.4% | | |
Growth #154 of 1484 companies
Payout #1117 of 1484 companies
Safety #1474 of 1484 companies
Price #1368 of 1484 companies
